The successful application of immunotherapy in a variety of solid tumors and the results of immunological checkpoint antagonists targeting programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) in metastatic breast cancer have raised interest in the area of immune-based strategies for breast cancer (11, 30). This evidence concerns the gene PDCD1 and breast carcinoma.